http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

330p. Pushing into new territory!

StockMarketWire.com
Allied Minds subsidiary SciFluor Life Sciences has been awarded a US patent covering the novel compound SF0034, a potent and selective neuronal potassium channel activator, designed to be a significantly improved version of the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA).

POTIGA was approved in 2011 for treatment of partial-onset epilepsy in adults, but its clinical use was severely restricted in 2013 due to latent toxicities which are not thought to be associated with its mechanism of action.

Numis note today:
"US universities and federal research laboratories spend over $170bn pa on research, and Allied Minds has built a network of over 60 such organisations from which it identifies novel IP and technologies. It forms companies around this IP, providing funding, management and legal and back office support for c.80-100% of the equity. Allied Minds has formed 21 subsidiaries to-date, with its holdings valued around $411m and with another c.$175m cash able to be deployed. The company has almost $250m of capital to invest in its existing portfolio and to develop new companies, so we believe that it is well capitalised to continue to build value. We value Allied Minds at 455p/share, implying 2.5x based on an assumption of 10-year IRR of 26% (compared to c.60% historical IRR), and initiate research coverage with a Buy rating.
The largest two holdings are:
Spin Transfer Technologies (STT) has developed a next-generation memory technology, which potentially has speed, reliability, energy consumption and cost benefits over incumbent technologies – we estimate that the addressable market is over $70bn. The company has already made significant technical progress and has recently been funded for the next phase of development, which should result in prototype products shipping in late CY15. It is most likely that an IP business model will be used, where STT licenses the technology to existing players in the memory market and earns royalties on chip sales (similar to ARM). However, the company may be acquired by one of those players if momentum around its technology continues to build.
RF Biocidics (RFB). With one in six people per year suffering from food-borne illnesses, and increasing regulatory emphasis on prevention, we believe that food disinfection will remain a growing trend. Existing disinfection methods have significant drawbacks, so RF Biocidics has developed a new system that uses radiofrequency. This has been integrated into two products that have already been sold to some major food producers.
Forecasts. Allied Minds' control over its subsidiaries means it consolidates their accounts, thus showing investment as operating and investing cash outflows. We model STT and RFB together generating $60m of revenue by 2018, which helps to offset an investment rate we model at $50-60m pa. Key risks include unanticipated technical hurdles at STT and slower commercial adoption of RFB's products.

Now more than doubled since the float. Currently 435p mid .

Has now passed the Numis price target of 455p. Possibly getting a little ahead of itself now? Consolidation (pause for breath) would make me happy now!

Looks like you have been on your own here HARRY , good pick .

Thanks jimmy. Going like a train! Trouble is, I have no idea why! No news, yet sp now surged past the £6 level.

Yes - fancy keeping these to yourself Harry! :-)

5th Sept was your last look skinny and you passed! On my part this is luck more than judgement! It's going up relentlessly but I don't really know why!!! Even the last broker note is not particularly enlightening on how it has valued the stock.

Well he posted 18 times over the last 6 months and we ignored him !!

Possibly now due to this:
"26-Feb-2015
Optio Labs Names Former Samsung Executive Bryan Glancey as Chief Technology Officer."

Though even ALM are cautious about their strategy!
"Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise."

Harry - I can only echo what I posted then - well done!

Brokers still some way behind the curve - as per normal.

Too far, too fast. Nice and steady preferred!

Boston (March 10, 2015) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, announced the formation of BridgeSat, Inc., which is building an optical connectivity system to improve the wireless transfer of data from satellites.

BridgeSat co-invented the technology with The Aerospace Corporation as part of a commercialization collaboration for the portfolio of innovations created at the federally funded research and development center (FFRDC). Aerospace has a long history of developing technologies for space, including 15 years of experience building small satellite technologies for both commercial and government entities.

"The Aerospace Corporation is a key player and leader in all aspects of space communication systems and technologies," said Dr. Sherrie Zacharius, Vice President of Technology and Laboratory Operations. "Through our robust research and development endeavors, we have established a rich portfolio of innovative building-block technologies applicable to broad public needs. This collaboration with Allied Minds, which led to the formation of BridgeSat, provides an avenue for technology transfer to the commercial sector for the common good."

"Our research with The Aerospace Corporation has allowed us to explore new, more effective options for LEO data transmissions," said John Serafini, Vice President at Allied Minds. "At BridgeSat, we believe we've solved challenges including size, weight, cost and power bottlenecks that had traditionally hampered optical-based data downlink, as the technology ultimately offers substantial benefits over traditional RF downlink."

Demand for accurate and frequent data collection from LEO satellites is expected to accelerate aggressively over the next decade amidst declining costs for building and launching satellites. BridgeSat has partnered with Draper Laboratory to develop the system that will provide an alternative downlink mechanism that is faster, more secure, and available at a lower cost to traditional radio-frequency transmissions.

"Draper's expertise in space systems technologies, optics and secure digital data links, as well as its experience in applying its capabilities to expanding commercial markets, will help BridgeSat mature its concepts throughout development and operations," said Dr. Seamus Tuohy, director of Space Systems at Draper Laboratory.

BridgeSat has also engaged with Dr. Kerri L. Cahoy, Assistant Professor of Aeronautics and Astronautics at the Massachusetts Institute of Technology (MIT). Dr. Cahoy will serve as a Senior Advisor to the company. BridgeSat has optioned a relevant selection of intellectual property from Cambridge, Massachusetts-based MIT.

"Optical communications offer a significant advantage in both resource utilization and security. We are innovating to improve and miniaturize spacecraft-pointing capabilities, an important enabler for higher-rate narrow beam optical systems, improved transmitter efficiency and the development of low-cost, easily deployed, and effective ground systems," said Dr. Cahoy.

BridgeSat, Inc. is a subsidiary of Boston-based Allied Minds. More information about the company and its research can be found www.BridgeSatInc.com.

StockMarketWire.com
Allied Minds, an innovative US science and technology development and commercialisation company, will announce its full year 2014 results at 7 a.m. on 28 April.

Allied Minds will also host a capital markets day event on the same day, to be held at Etc. Venues St Paul's, 200 Aldersgate Street, EC1A 4HD.

Allied Minds' Subsidiary SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
· SciFluor's recent advancements in its pipeline, comprised of two lead compounds and additional discovery assets using the strategic incorporation of fluorine to create best-in-class drugs, generated investor interest.
· SciFluor's plans to develop fluorine-containing new chemical entities (NCEs) across multiple disease states will benefit from the addition of William Koster, whose accomplishments include success in senior executive roles in small molecule drug discovery and early clinical development at Neurogen Corp. and Bristol-Myers Squibb Co.

Appointment of New Non-Executive Chairman
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, today announces that Mr. Peter Dolan will be appointed to the role of Non-Executive Chairman of the board of directors of the Company ("Board"), with effect from the conclusion of the Company's Annual General Meeting on 28 May 2015. Mr. Dolan will replace the current Executive Chairman, Mr. Mark Pritchard, who will remain on the Board in an executive capacity in the short term but intends to step down from the Board later in the year, although he is expected to continue to be actively engaged with the Company. Mr. Pritchard founded Allied Minds in 2004 and has been directly involved in its strategic direction and growth since inception, most recently taking the role of Chairman of the Board as the Company listed on the Main Market of the London Stock Exchange in June 2014. The appointment of Mr. Dolan, an independent non-executive director, will further the Company's compliance with best practices of the UK Corporate Governance Code.

Placing of Shares in Allied Minds plc
20 May 2015

Further to the announcement released on 19 May 2015, Invesco Asset Management Limited, in its capacity as agent for and on behalf of its discretionary managed clients ("Invesco") has sold 16 million ordinary shares of Allied Minds (the "Placing Shares") at a price of 565 pence per share, raising gross sale proceeds of £90.4 million.

The sale on behalf of Invesco was completed via an accelerated bookbuild to institutional investors conducted by Jefferies International Limited ("Jefferies") and Numis Securities Limited ("Numis") as joint bookrunners (the "Placing"). Allied Minds will not receive any proceeds from the Placing.

Following settlement of the Placing, Invesco's discretionary managed clients are expected to hold approximately 34.5 per cent. of the Company's issued share capital.

The proceeds of the Placing are payable in cash on usual settlement terms, and closing of the Placing is expected to occur on a T+2 basis on 22 May 2015, subject to the satisfaction or waiver of certain customary conditions.

Invesco has indicated that, following completion of the Placing, it intends to remain a significant, long term shareholder of the Company.

Annual General Meeting
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, is holding its Annual General Meeting (AGM) today. No new information on current trading will be given during the meeting.

The Company will release its 2015 Half Yearly Report on 27th August 2015.

StockMarketWire.com
Allied-Bristol Life Sciences - a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Company - has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine.

Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF).

HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.

Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children's Hospital, Professor Whitman's lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway.

Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases.